X

Drug Profile

Tenecteplase biosimilar - Hetero Biopharma

Latest Information Update: 08 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hetero Biopharma
Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
Mechanism of Action Plasminogen activators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Myocardial infarction

Most Recent Events

10 Sep 2023 Clinical trials in Myocardial infarction (IV), before September 2023
10 Sep 2023 Pharmacokinetics data from clinical trial inMyocardial infarction presented at the 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com